{"text": "                                                                                                                                                                                                                                              .,~\r\n                                                                                                                                                                                                                                              , '''-J:,\r\n                                                                                                                                                                                                                                              \"11\r\n Aids pandemic\r\n POSITIVE MOVE: Researchers Harriet Robinson and Rama Amara examine a plate used to measure immune cells at a lab in Atlanta. At right is one of                      ~1l-ear'sKenyan volunteers,              Dr Pamela Mandela, seated.\r\n                                                                                                                                                                           i-'\"'\r\n Calling volunteers for Aids trials\r\n Hot on the heels of Nairobi experiments, the joint UK-Kenyan team now W\r\n Britons for the second and key phase of their 'encouraging' HIVvaccine re\r\n         By PAUL REDFERN,                       repeated exposure to the HIV virus.                                                          around half the usual time taken.                      from contracting'            US or   will merely\r\n    Nation correspondent, London                   The cost of the research conducted so                                                       The woi~ i~ based around a group of                  help them live 10\r\n                                                far is estimated at around \u00a32.5 million                                                      Nairobi piQ.\u00a7titutes who have not                         Research invo            monkeys has\r\n The joint UK and Kenyan initiative to          (Sh285m).                                                                                    become HIV positive despite having up                  proved encouraging, .gh        not conclu-\r\n find an Aids vaccine is now entering              Traditional Aids vaccine research has                                                     to 10 sexual partners a day. The key                   sive. But critically several other groups\r\n phase two of the trial stage, with 120         concentrated on boosting the body's                                                          findings were that the w ' nhave HIV-                  are following the lead of the Oxford;\r\n healthy British volunteers being sought        immune system but the Oxford/Nairobi                                                         specific killer T-cells In' ,   ies.                   Nairobi gr.oup.\r\n for further trials.                            groups' research contains two distinct                                                          A small number of th       .      ever,                                 \"'1.\",\r\n    Recently, the Nairobi team also asked       components - a DNA vaccine that                                                              recently became HIVp               :. ter                                  tr'~\r\n                                                                                                                                                                                                            .the.same\r\n                                                focuses the immune response against\r\n for Kenyan volunteers for the next                                                                                                           r~Wrning to, prostitution, in' whit                                    that other groups are\r\n                                                HIV and a modified smallpox vaccine\r\n phase of the trials.                                                                                                                      , .~Qnsidered at the time to be a serious                going\u00b7            .\u2022. e\u00b7ttack so if we cod\r\n                                                that boosts the response.\r\n    Prof Andrew McMichael, who heads                                                                                                          blow to the research.      -                          it up so '.          Way get it right,\" he\r\n                                                   The research team is said to have\r\n the Medical Council's human immunol-                                                                                                            But the scientists now believe that                said. \"The tp,ought that would keep mt\r\n                                                found by trial and error that this primel\r\n ogy unit at Oxford University, said the                                                                                                      immunity is not conferred by a special                awake at night is what if this strategy\r\n                                                boost combination       achieves better\r\n first trials within Kenya had \"similar                                                                                                       gene, but is temporary and can fade                   doesn't work at. all? Because then we'd\r\n                                                results than using the two vaccines in\r\n encouraging results\" to those under-                                                                                                         after time.                                           have .to go back to the anti-body\r\n                                                isolation.\r\n taken earlier in the UK.                                                                                                                        They say th~t this acquired immunity               approach.\"\r\n                                                   At present the researchers' combined                                                       needs to be boosted, just as with some                  In the latest trials, there is no live HI \\\r\n Sat t f a 'n                                   vaccine is targeted at the HIV sub-type                                                       vaccines. The researc\\\\\"c'toncentrates, _             material within the vaccine being used\r\n    e yo v CCI e           .,           .       known as A, which is prevalent in east-         Prof McMichael: We're targeting sub\u00b7          not on stimulating the boli\u00a5,-&.~tibo6ies   so participants should not be at risk.\r\n Now th~ second stage of tnals ISto be.gm       ern and central Africa. But it is believed      type A, prevalent in eastern Africa          - but on arming the bodY~J::\"celfs to\r\n by seekmg 120 people. to help confirm          the vaccine can be adapted to work                                                                                                          Scientists say that the timing and dos\r\n                                                                                               involving patent rights between Kenyan        combat HIV.~'                             , ' e of vaccines are crucial to the overa\r\n the safety of the v~ccme bemg devel-           against sub-type C, found in South Afri-                                                                                                                                          i\r\n                                                                                               and British scientists, the Financial            Nevertheless, Prof McMichael is stilt'         ssof a trial such as this. They car\r\n oped, as well as to gIVe researchers new       ca or sub-type B which is common in                                                                                                            is\r\n inform~tion on the dosage and. boost~r         E~rope.           '                            Times said recently that the vaccine has      uncertain that this approach is right. It            tablish whether the vaccine work~\r\n                                                                                               so far progressed from the laboratory to      still unknown, for example, whether the               at procedures should be in plac(\r\n th~t mIght ~e needed to make Immum-              While there have been allegations of\r\n                                                                                               phase' one trials in a record two years,      vaccine will completely protect people                   care\r\n satIon effectIve.                              delays in research and difficulties                                                                                                                th      programmes.\r\n    The Guardian newspaper says that\r\n several human trials for vaccines using\r\n different techniques are now under way,                                                                                          INSIGHT\r\n but the British and Kenyan researchers\r\n research might also help to develop vac-\r\n are working on a vaccine targeted at the                           Nagging questions about~thestudy\r\n strain prevalent in East Africa. The\r\n cines that can combat several stains at                                                                                          j   ,\r\n  one time.                                                  any queries have been raised over the HIVI        to be approved by the Kenyatta National Hospital                     What sort of side effects might it cause?\r\n     Prof McMichael says he is pleased             M        Aids vaccine trials that started in Kenya two      Ethics and Research Committee and the National\r\n  with the results so far, but adds: \"We                                                                       Council for Science and Technology.                                  Some particip<mt~may experience pain, tenderness,\r\n                                                            years ago. Following are key answers given                                                                              redness or swellMg at the injection site, or mild flu-\r\n  should emphasise that there is still a           by a team of scientists at the Department of Medical\r\n  very long way (to go), with several more                                                                     How will the vaccine be administered?                                like symptoms such as headache and fever. Others\r\n                                                   Microbiology, Nairobi:\r\n  trials to carry out before this can be con-                                                                  It will be given as an injection into the skin over the              may experience no side effects at all.\r\n~red        a vaccine.\"                                                                                                                                                                For the first two days after immunisation, volun-\r\n                                                   Q. Why is tWs vaccine being tested in Kenya?                shoulder. One will receive two injections four weeks\r\n                                                                                                                                                                                    teers will be asked to come to the clinic for review.\r\n                                                   A. Because it has been specifically designed to be          apart.\r\n Priming killer T-cells                                                                                                                                                             They will also be given a telephone number to call in                 ,\r\n                                                   used in the country. The vaccine is based on the most                                                                            case th:e~ are any problems .\u2022                                        I\r\n In the first stage of the trials volunteers       common type of HIV circulating in Kenya. Local sci-         Howkroyoes       the trial vaccine stay in the body?\r\n were injected with the first component            entists are working in collaboration with international     Just for a Short time. It is the immune system's                     WillAdl,.peoPlewho receive the vaccine react in the\r\n of the vaccine, which isilimed at priming         partners to develop a safe and affordable preventive        response that is important.                                          sanf~ay?\r\n large numbers of killer T-cells to identify       vaccine.\r\n and destroy cells infected with HIV                                                                           Will the vaccine protect against HIV/Aids?                            No;~dividuals may react differently to a vaccine.\r\n                                                                                                                                                                                   ,~      is the case for potential side effects and for\r\n before these can produce new viruses.             Has the vaccine been tested somewhere else?                 We do not know yet if it will protect vaccinated indi-\r\n                                                                                                                                                                                     ~ts\u00b7the     vaccine may have on one's immune sys-\r\n    The first stage of the vaccine intro-          Yes, it is being tested in a Phase I trial in England.      viduals from getting HIV/Aids. Volu~teers are.                        tem. Both genders are participating in the trials to\r\n duces about 15 per cent of the HIV                                                                            advised to continue to observe the reco,         d\r\n                                                                                                                                                                                    ensure there are no important differences in reaction\r\n genes into the skin or muscle. The                Who are the volunteers there?                               preventive methods and keep the ris.kQf1ilV infec-                       e vaccine.\r\n genetic material is taken up by cells in          They are individuals residing in Britain. Anybody can       tion low.\u00b7\u00b7\u00b7\"'\r\n the body, which then produces HIV pro-            participate, regardless of race, ethnicity or gender,                                                                            Can the vaccine cause HlV/Aids?\r\n teins that stimulate the immune system            provided they meet the trial e~try criteria. Volunteers     Is the vaccine safe?                                                 No, it cannot. It is ~Jtiticially made and there is no\r\n to react against the virus.                       are healthy men and women at low risk of acquiring          Yes. Befor~jt was approved for human testing it was                  risk of that.\u00b7-         ine does not contain killed or\r\n   When volunteers were injected with              HIV who are interested in helping ensure that a pre-        extensi     ,.' udied in animals alld no significant side            weakenedddoes          not                    material\r\n the first component of the vaccine, most          ventive vaccine is developed soon.                          effec     .' observed. The va.cciile has beel)                       from HIV-i ected indivi\"                      dividuals\r\n of them exhibited an immune response                                                                          a          for Phase 1 testmg in humans in England\r\n                                                                                                                                                                                    that were found to be resist\r\n similar to that of the group of around 60         Has the study been approved by Kenyan authoritie            ,       unteers have been enrolled, vaccinated and                     Nor do~sit contain any blood\r\n Nairobi prostitutes who have resisted             Before the Nairobi HIV vaccine trial can start; it has      followed up for several months.                                      nents,.\r\n infection over many years despite\r\nPage \f\r\n\r\n\r\n-------------------Trial Version-----------------------\r\n\r\nConvert PDF to Text Desktop Software.\r\n\r\nCopyright Convertpdftotext.net 2014.\r\n\r\nTo remove these lines, please activate your software from http://www.convertpdftotext.net/buynow.htm\r\n\r\n-------------------------------------------------------"}